Company intelligence / Profile preview
Citi Pharma
- Ownership
- Private
- Employees
- ~519
- Development stage
- Other
Overview
Citi Pharma is the largest API manufacturer in Pakistan with a ~45% share of the national API sector, focused on high-demand APIs and expanding into the formulation (finished drug) market, including future projects in insulin, biotech, and vaccines. It reported strong growth (4-year CAGR ~37%) and is expanding R&D and bioequivalence infrastructure, but has disclosed no current clinical trial outcome data[2][3].
- Therapeutic areas
- CardiovascularEndocrinologyGastroenterologyInfectious DiseasesNeurologyMetabolic Disorders
- Modalities
- Small moleculeBiologic (planned; insulin, vaccine)
- Industry
- Biotech
Drug pipeline
6 assets5 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Citi Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Citi Pharma.